Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day, Price Target Raised to $225 From $144

11/22/2021 | 08:46am EST


ę MT Newswires 2021
All news about ALNYLAM PHARMACEUTICALS, INC.
07:50aHC Wainwright Boosts Price Target on Alnylam Pharmaceuticals to $350 From $250, Keeps B..
MT
01/18Morgan Stanley Adjusts Alnylam Pharmaceuticals' Price Target to $215 from $226, Keeps O..
MT
01/17Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
AQ
01/14Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
BU
01/14Alnylam Pharmaceuticals, Inc. to Present Full 18-Month Results from the HELIOS-A Phase ..
CI
01/10Alnylam Announces Preliminary Fourth Quarter and Full Year 2021 Global Net Product Reve..
AQ
01/10ALNYLAM PHARMACEUTICALS : Announces Preliminary* Fourth Quarter and Full Year 2021 Global ..
PU
01/10Alnylam Pharmaceuticals Reports Higher Preliminary 2021 Net Product Revenue
MT
01/09Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Rev..
BU
01/09Alnylam Pharmaceuticals, Inc. Announces Sales Results for the Fourth Quarter and Full Y..
CI
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 821 M - -
Net income 2021 -761 M - -
Net cash 2021 1 321 M - -
P/E ratio 2021 -21,5x
Yield 2021 -
Capitalization 16 579 M 16 579 M -
EV / Sales 2021 18,6x
EV / Sales 2022 12,4x
Nbr of Employees 1 453
Free-Float 99,4%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | ALNY | US02043Q1076 | MarketScreener
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 138,62 $
Average target price 206,57 $
Spread / Average Target 49,0%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet President, Chief Operating Officer & Director
Akshay K. Vaishnaw President-Research & Development
Jeffrey V. Poulton Executive VP, Chief Financial & Accounting Officer
Michael W. Bonney Independent Director
Pushkal Garg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-18.26%16 579
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
ICON PUBLIC LIMITED COMPANY-17.00%20 923